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Abstract
Purpose The current cut-offs for the diagnosis of adrenal insufficiency (AI) have been established using outdated immunoassays.
We compared the cortisol concentrations measured with Roche Cortisol I (R1), the newly available Roche Cortisol II (R2), and
liquid chromatography tandem mass spectrometry (LC-MS/MS), the gold standard procedure to measure steroids in patients
undergoing the corticotropin (ACTH) test.
Methods We enrolled 30 patients (age 47 ± 21 years) referred to undergo the ACTH test (1 or 250 μg). Cortisol was measured at
0, 30, and 60 min after stimulation with R1, R2, and LC-MS/MS. AI was diagnosed for R1-stimulated peak cortisol concentra-
tions < 500 nmol/L.
Results Mean cortisol concentrations measured with R2 and LC-MS/MS were comparable, while mean cortisol concentrations
measured by R1 were higher than those of both R2 and LC-MS/MS (respectively, basal 411 ± 177, 287 ± 119, and 295 ±
119 nmol/L; at 30 min, 704 ± 204, 480 ± 132, and 500 ± 132 nmol/L; at 60 min, 737 ± 301, 502 ± 196, and 519 ± 201 nmol/L,
p ≤ 0.01 for R1 vs. both R2 and LC-MS/MS at each point). Considering the 500 nmol/L cortisol peak cut-off, AI was diagnosed in 5/
30 patients using R1 and in 12/30 using R2 (+ 140%). Based on the correlation between R1 and R2, the threshold of 500 nmol/L
became 351 nmol/L (12.7 μg/dL) when cortisol was measured with R2, and 368 nmol/L (13.3 μg/dL) with LC-MS/MS.
Conclusions The use of more specific cortisol assays results in lower cortisol concentrations. This could lead to misdiagnosis and
overtreatment when assessing AI with the ACTH test if a different cut-off for cortisol peak is not adopted.
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Introduction
Adrenal insufficiency (AI) is a potentially life-threatening
medical condition in which cortisol secretion is impaired be-
cause of adrenal (primary adrenal insufficiency, PAI) or
pituitary failure (secondary adrenal insufficiency, SAI).
Although morning serum cortisol concentrations are helpful
to determine hypothalamic-pituitary-adrenal axis function, the
evidence in the literature is as yet insufficient to support the
use of basal cortisol concentrations alone in order to either rule
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out or confirm AI [1–5]. Diagnosis is mainly based on mea-
suring cortisol concentrations after a stimulation test: the stan-
dard dose (250 μg) corticotropin (1–24 ACTH) test (SDCT)
represents the gold standard dynamic test for PAI, while the
insulin tolerance test (ITT) is the gold standard if SAI is
suspected [1–5]. However, ITT is cumbersome and contrain-
dicated in many patients. SDCT and the low-dose (1 μg) cor-
ticotropin test (LDCT) have been validated against ITT, and
they are the most widely used tests in clinical practice because
of their higher safety and tolerability [6–8]. Interpreting cut-
off peak values after stimulation is also challenging [9].
Traditionally, cortisol peak concentrations > 500 nmol/L
(18.1 μg/dL) are accepted in the guidelines as evidence of
appropriate cortisol secretion, even if the cut-off values for
exclusion of AI vary widely in different studies, from
418 nmol/L (15.2 μg/dL) to 750 nmol/L (27.1 μg/dL) accord-
ing to the sensitivity/specificity chosen, timing of the peak (30
vs. 60 min), and assay used [10–13]. It must be emphasized
that the thresholds for the need for replacement therapy have
been established using mainly outdated radioimmunoassays,
whose main limitation was the interference caused by com-
pounds with structural similarity to the target molecule (e.g.,
endogenous steroids, drugs, or natural products) due to the use
of polyclonal antibodies. Liquid and gas chromatography tan-
dem mass spectrometry (LC-MS/MS and GC-MS/MS) are
currently considered the gold standard procedures for cortisol
measurement because they have demonstrated low cross-
reactivity with other steroids; however, they are still not wide-
ly available [10]. Recently, a highly specific monoclonal and
more easily available immunoassay by Roche, cortisol II (R2),
calibrated on GC-MS/MS, has been released [14–18]. Using
the R2 assay, new peak cortisol cut-offs as low as 375 and
351 nmol/L (13.6 and 12.7 μg/dL, respectively) have been
proposed for the diagnosis of AI by two preliminary studies
[17, 18]. These values are notably lower than the cut-offs
suggested by the current guidelines and, thus, need to be up-
dated. This issue is crucial for patients because of the diag-
nostic and therapeutic implications.
The aim of this study was to measure cortisol concentra-
tions after ACTH stimulation in a cohort of patients referred to
our center for suspected AI and to compare the results obtain-
ed with old and new assays. We evaluated how the traditional
diagnostic thresholds applied to second-generation assays in-
fluence the number of AI diagnoses.
Material and methods
Subjects
In our study, we enrolled 30 consecutive adult patients re-
ferred to the Endocrinology Unit at Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Milan, Italy, for
suspected AI to undergo the ACTH test during a period of
3 months. Pediatric patients and subjects with liver or renal
impairment, or with abnormal albumin concentrations, or tak-
ing estrogen or other drugs that could interfere with cortisol
secretion or dosage were excluded. Approval from the insti-
tutional review board was not required for this study because it
was considered a routine activity focused on the possibility of
introducing a new technology and aligning different methods,
for which no extra biological samples or sensitive data were
necessary.
Methods
In all the subjects studied, we performed the ACTH test in the
fasting state between 08.00 and 09.00 a.m. The patients lay
supine on a bed with an intravenous catheter inserted in a
forearm vein and kept clean by slow saline infusion for
30 min (basal condition). For SDCT, 1 mL of cosyntropin
(Synacthen© 0.25 mg/mL, Sigma-Tau) was injected as a bo-
lus intravenously. A 1-μg dose was prepared just before the
administration as follows: 1 mL of Synacthen© 0.25 mg/mL
was injected into 249 mL of sterile 0.9% saline, yielding a
1 μg/mL solution for administration. Blood serum samples
were taken in the basal condition and 30 and 60 min after
stimulation. In our center, the indication for cortisol replace-
ment therapy was set at R1 stimulated peak cortisol concen-
trations < 500 nmol/Lmeasured by R1, in accordance with the
literature and with our experience [1–3, 11]. Although partial
AI was a possibility, by using the 500-nmol/L cut-off after
stimulation, we had no reported adrenal crisis in our series.
Assays
All hormone measurements were performed in the same
laboratory.
Serum cortisol concentrations were measured by two as-
says of the same manufacturer measured on the same analyzer
(Elecsys Cortisol immunoassay, Roche Diagnostics,
Mannheim, Germany, on CobaS E 602): R1, a first-
generation electrochemiluminescence polyclonal immunoas-
say (ECLIA) with an inter-assay CV ranging from 1.4 to
2.8%, an intra-assay CV ranging from 1.0 to 1.7% and lower
detection limit of 0.5 nmol/L, and R2, the second-generation
monoclonal immunoassay Elecsys Cortisol II with limit of
detection 1.5 nmol/L, limit of quantitation 2.0 nmol/L, inter-
assay CV ranging from 1.9 to 10.1% and intra-assay CV from
1.5 to 5.4%.
Serum cortisol concentrations were also measured by LC-
MS/MS using a IVD-MS steroids in serum kit (MassChrom,
Steroids in Serum/Plasma, Chromsystems, Gräfelfing,
Germany). Chromatographic separation and mass spectromet-
ric detection of samples were performed with high-
performance liquid chromatography (HPLC, Shimadzu,
Hormones
Milano, Italy) interfaced with a Sciex 4500 MD mass spec-
trometer (Sciex, Milano, Italy). Samples were prepared ac-
cording to the manufacturer’s instructions. In short, 500 μL
of each sample, calibrators, or serum quality control (QC) was
placed in a solid phase extraction sample plate previously
equilibrated; 50 μL of a deuterated internal standard mix so-
lution, as well as 450 μL extraction buffer, was added. The
sample plate was then vortexed and centrifuged. The extrac-
tion media was evaporated under nitrogen to dryness,
reconstituted, and directly injected into an HPLC system
equipped with an analytical column (operating at 32 °C) for
peak separation. Mobile phases A and B (provided with the
kit) were used for the chromatographic separation. For cali-
bration, a blank calibrator matrix and six multilevel serum
calibrators, provided with the kit, were used. To assess
within- and between-run precision and accuracy, three certi-
fied serum QCs provided with the kit were used; these were
certified by the National Institute of Standards and Toxicology
(NIST) in order to promote international standardization. The
limit of quantitation provided by the kit was 4 nmol/L, while
our inter-assay CV ranged from 4.0 to 4.4% and intra-assay
CV from 1.1 to 3.3%, based on three replicate and three ana-
lytical sessions (N = 12). During routine analyses, calibration
curves and QCs were run within each set of unknown sam-
ples. A typical analytical sequence consisted of a calibration
curve, followed by unknown samples, with QC samples re-
peated every ten unknown samples, followed by a second
calibration curve.
Statistical analysis
Statistical analysis was performed by SPSS version 25.0 sta-
tistical package (SPSS Inc., Chicago, IL, USA), and
MedCalc statistical software for Windows (Ostend,
Belgium). Comparison of continuous variables was per-
formed using the t test or Mann-Whitney test, as appropriate.
The normality of distribution was checked by the
Kolmogorov-Smirnov test. Variables were expressed as
mean±standard deviation if normally distributed, and as me-
dian (interquartile range) if not normally distributed; the
comparison was performed using one-way Student’s t test
or the Mann-Whitney U test, respectively, as appropriate.
R1, R2, and LC-MS/MS cortisol concentrations were com-
pared with a nonparametric Passing and Bablok regression
analysis, a Cusum test, and Spearman correlation coeffi-
cients [19]. The Bland-Altman approach was used to assess
differences between the two methods by plotting the percent-
age difference between the two assays vs. the mean concen-
tration [20]. A p value less than 0.05 was considered signif-
icant. Using the obtained equations, we calculated the R2
and LC-MS/MS concentrations of cortisol corresponding to
the R1 cortisol concentration of 500 nmol/L.
Results
Fifteen patients (12/3 F/M, age 44.6 ± 24.8 years) underwent
SDCT for suspected non-classical congenital adrenal hyper-
plasia (NCCAH) (12/15) or suspected PAI following unilater-
al adrenalectomy (3/15). The remaining 15 patients (12/3
F/M, age 50.9 ± 16.7 years) underwent LDCT for suspected
SAI in an incidental radiological finding of empty sella (1/15)
or pituitary adenoma (10/15), or after 2 months following
(4/15) pituitary surgery. At the time of testing, six patients
were on glucocorticoid replacement therapy (cortisone ace-
tate, three patients as prophylaxis following adrenal surgery
and three patients because of a previous diagnosis of SAI).
Cortisone acetate mean dose was 25.0 ± 12.9 mg/day and
mean time on replacement therapy 66.3 ± 70.4 months; all
patients were on drug wash-out for 24 h before the test.
As expected, in the majority of patients undergoing LDCT,
cortisol peak occurred at 30 min, and in the majority of pa-
tients undergoing SDCT, at 60 min, regardless of the cortisol
measurement method used. Overall mean cortisol concentra-
tions measured with R1, R2, and LC-MS/MS were, respec-
tively, 411 ± 177 (14.9 ± 6.4), 287 ± 119 (10.4 ± 4.3), and 295
± 119 (10.7 ± 4.3) nmol/L (μg/dL) in basal conditions; 704 ±
204 (25.5 ± 7.4), 480 ± 132 (17.4 ± 4.8), and 500 ± 132 (18.1
± 4.8) nmol/L (μg/dL) at 30 min; and 737 ± 301 (26.7 ± 10.9),
502 ± 196 (18.1 ± 7.1), and 519 ± 201 (18.8 ± 7.3) nmol/L
(μg/dL) at 60 min after the ACTH test. Cortisol levels mea-
sured with different methods in the basal and stimulated con-
dition after LDCT and SDCT are reported in Table 1. The R1
cortisol concentrations were significantly higher than those of
R2 and LC-MS/MS at each time point (p < 0.001), while cor-
tisol concentrations obtained with R2 and LC-MS/MS using
both tests were comparable (Table 1).
For R1 vs. R2, Passing-Bablok intercept of the linear re-
gression was − 41.00 (95%CI: − 68.98; − 11.30) and the slope
was 1.54 (95% CI: 1.46; 1.61) (Table 2). Considering R2 as
the reference method, these results indicate the presence of a
constant bias, as well as a proportional bias, in R1, for which
values, according to the Bland-Altman plot, were approxi-
mately 36% higher (from 12.7 to 58.7%). A similar discrep-
ancy was observed over the whole range of concentrations
tested (Fig. 1a). The same response was obtained for R1 vs.
LC-MS/MS, in which the Passing-Bablok intercept of the lin-
ear regression was − 60.07 (95%CI: − 98.60; − 24.53) and the
slope was 1.52 (95% CI: 1.43; 1.62) (Table 2). Considering
LC-MS/MS as the reference method, these results indicate the
presence of both a constant and a proportional bias in R1,
whose values, according to the Bland-Altman plot, were ap-
proximately 32% higher (from 3.7 to 60.3%). A similar dis-
crepancy was observed over the whole range of concentra-
tions tested (Fig. 1b). For R2 vs. LC-MS/MS, Passing-
Bablok intercept of the linear regression was − 11.39 (95%
CI: − 28.23; − 0.42) and the slope was 0.99 (95% CI: 0.96;
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1.03) (Table 2). Considering LC-MS/MS as the reference
method, these results indicate the absence of a proportional
bias and the presence of a small constant bias for R2, whose
values, according to the Bland-Altman plot, were approxi-
mately 4% lower than those of LC-MS/MS (from − 24.0 to
16.5%). A similar discrepancy was observed over the whole
range of concentrations tested (Fig. 1c).
Based on the correlation between R1 and R2 cortisol con-
centrations, we calculated that the diagnostic threshold for AI
would be 351 nmol/L (12.7 μg/dL) if cortisol levels were
measured with R2 (Fig. 1a). Similarly, applying the correla-
tion between R1 and LC-MS/MS cortisol concentrations, we
found that the cut-off for diagnosing AI would be 368 nmol/L
(13.3 μg/dL) (Fig. 1b).
With the traditional 500 nmol/L (18 μg/dL), cut-off AI
would have been diagnosed in 5/30 patients (17%) using
R1, and 12/30 (40%) using R2, leading to a relevant increase
in AI diagnosis in our patient cohort (+ 140%). Clinical and
biochemical characteristics of the seven patients diagnosed as
AI by R2 but not by R1 are shown in Table 3.
Discussion
The main findings of our study are that R2 cortisol concentra-
tions were significantly lower than those of R1 and much
more similar to those obtained by LC-MS/MS. By using the
current cut-off of 500 nmol/L, we would have overestimated
the presence of AI in our population, with consequent over-
treatment by non-indicated hydrocortisone replacement
therapy. Based on the correlation between R1 and R2 cortisol
concentrations, the threshold of 500 nmol/L became
351 nmol/L (12.7 μg/dL) when cortisol levels were measured
with R2 and 368 nmol/L (13.3 μg/dL) with LC-MS/MS.
These apparently low levels should not be surprising if we
consider that the mean R2 cortisol concentrations were about
36% lower than those of R1 at all time points. Considering
LC-MS/MS as the reference method, the Bland-Altman plot
and the Passing and Bablok regression analysis highlighted
better performance for R2 compared with R1. This result con-
firms the strong correlation between R2 and LC-MS/MS, as
previously reported [16, 17].
These values are fully in agreement with those recently
found by Raverot and Kline [17, 18]. Raverot et al. analyzed
samples from 109 patients undergoing the ACTH test (dose
not specified) and ITT by ROC curves, using the 500-nmol/L
cut-off for cortisol peak assessed by R1 as reference. They
found a 374-nmol/L (13.6 μg/dL) threshold for R2 to have
100% sensitivity and 93.3% specificity, whereas a cut-off of
350 nmol/L (12.7 μg/dL) would enable 100% specificity, re-
ducing sensitivity to 85% [17]. Kline et al. studied 82 patients
undergoing various tests—ITT, glucagon stimulation, SDCT,
or LDCT—and compared cortisol peak concentrations after
stimulation tests measured by R1 and R2, as performed in our
study. They obtained a new peak cortisol cut-off of
351 nmol/L (12.7 μg/dL) [18].
In our study including both SDCT and LDCT, we found
exactly the same cut-off of 351 nmol/L (12.7 μg/dL) for cor-
tisol measured by R2. We also calculated the cut-off for cor-
tisol measured by LC-MS/MS as 368 nmol/L (13.3 μg/dL),
Table 1 Biochemical evaluations at basal and stimulated conditions
Time Cortisol R1 (nmol/L) Cortisol R2 (nmol/L) Cortisol LC-MS/MS (nmol/L) p value (R1 vs. R2 and LC-MS/MS)
LDCT
N = 15
0′ 306 (193) 212 (102) 229 (116) < 0.001
30′ 599 (315) 414 (163) 436 (199) < 0.001
60′ 458 (386) 317 (229) 378 (215) < 0.001
SDCT
N = 15
0′ 516 (348) 348 (190) 359 (182) < 0.001
30′ 789 (190) 538 (124) 552 (119) < 0.001
60 927 (163) 635 (116) 646 (168) < 0.001
LDCT, low-dose (1 μg) ACTH test; SDCT, standard dose (250 μg) ACTH test; R1, Roche I; R2, Roche II cortisol assay; LC-MS/MS, liquid chroma-
tography tandem mass spectrometry; AI, adrenal insufficiency. Cortisol levels are expressed as median (interquartile range); categorical variables are
expressed as number (percentage). Conventional unit conversion factors, SI cortisol levels/27.6
Table 2 Passing-Bablok correlation parameters
Passing-Bablok
regression equation
95% CI of the
intercept
95% CI of the slope Cusum test for linearity Spearman correlation
coefficient (significance)
R1 vs. R2 y = − 41.00 + 1.54x − 68.98; − 11.30 1.46–1.61 N.S. deviation from linearity (p = 0.991) 0.972 (p < 0.001)
R1 vs. LC-MS/MS y = − 60.07 + 1.52x − 98.60; − 24.53 1.43–1.62 N.S. deviation from linearity (p = 0.635) 0.960 (p < 0.001)
R2 vs. LC-MS/MS y = − 11.39 + 0.99x − 28.23; − 0.42 0.96–1.03 N.S. deviation from linearity (p = 0.459) 0.973 (p < 0.001)
R1, Roche I; R2, Roche II cortisol assay; LC-MS/MS, liquid chromatography tandem mass spectrometry
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which tends to be slightly—but not significantly—higher than
R2, as shown by other authors [21].
Few data are available on cortisol concentrations measured
with R2 in healthy subjects; to our knowledge, the only study
Fig. 1 Bland-Altman plots to
identify relative differences
between R1 and R2 (panel a); R1
and LC-MS/MS (panel b); and
R2 and LC-MS/MS (panel c).
Mean differences are represented
with solid blue lines, and 95%
limits of agreement are
represented with dashed lines.
Passing-Bablok correlation be-
tween the serum levels of cortisol
assessed by R2 vs. R1 (panel a);
LC-MS/MS vs. R1 (panel b); and
LC-MS/MS vs. R2 (panel c). The
correlation lines are represented
with solid blue lines, and the 95%
limits of agreement are represent-
ed with dashed lines. The dotted
lines indicate lines of identity
Table 3 Clinical and biochemical characteristics of patients diagnosed as AI by R2 but not by R1
Patient Age Sex Diagnosis Test
type
Ongoing GC
replacement
R1 (nmol/L) R2 (nmol/L) TM (nmol/L)
0′ 30′ 60′ 0′ 30′ 60′ 0′ 30′ 60′
P1 76 M Unilateral adrenalectomy for subclinical
hypercortisolism by adrenal adenoma
SDCT Yes 516 585 596 403 417 442 425 477 483
P2 61 M GH-deficiency + hypogonadism + hypothyroidism
following pituitary surgery
LDCT No 425 704 657 259 453 419 276 508 444
P3 40 F Microprolactinoma LDCT No 248 599 475 201 414 359 218 436 384
P4 75 M GH-deficiency + hypogonadism following pituitary
surgery
LDCT No 306 638 577 207 464 386 229 472 400
P5 50 F Microprolactinoma LDCT No 268 541 395 212 378 293 174 223 320
P6 65 F Non-classical congenital adrenal hyperplasia SDCT No 546 679 693 326 295 353 337 408 373
P7 55 F Partial empty sella LDCT No 389 690 458 237 461 317 271 527 378
AI, adrenal insufficiency; LDCT, low-dose (1 μg) ACTH test; SDCT, standard dose (250 μg) ACTH test; GC, glucocorticoids
R1, Roche I cortisol assay;R2, Roche II cortisol assay; LC-MS/MS, liquid chromatography tandemmass spectrometry. *p < 0.001 for R1 vs. both R2 and
LC-MS/MS cortisol concentrations. Conventional unit conversion factors, SI cortisol levels/27.6
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to date was carried out by Ueland et al. They enrolled 121
volunteers (M=F, mean age 40 years) to undergo SDCT and
evaluated stimulated cortisol cut-off for R2 and LC-MS/MS
(using a different spectrometer from ours). They found that the
2.5th percentile of cortisol values at 30 and 60 min following
SDCT were 440 and 548 nmol/L (15.9 and 19.8 μg/dL) by
R2, and 412 and 485 nmol/L (14.9 and 17.6 μg/dL) by LC-
MS/MS, respectively [15].
In our study, none of the patients undergoing SDCT was
diagnosed as AI when measuring cortisol levels by R1 and
using the traditional cut-off. However, based on R2 cortisol
concentrations and considering the cut-offs of 440 and
548 nmol/L after 30 and 60 min, respectively, AI would have
been diagnosed in two patients (P1 and P6, Table 3). P1 had
recently undergone unilateral adrenalectomy for a cortisol-
secreting adenoma, which is often followed by transient
hypoadrenalism lasting from a few months to several years
[22]. P6 received a subsequent diagnosis of NCCAH with
double heterozygosity for CYP21A2 mutations in c.290-13
A/C>G and c.841 G>T (leading, respectively, to 0% and
20–50% residual enzyme activity), which is potentially asso-
ciated with AI. We cannot exclude that, by using R1, we
would have missed the diagnosis of AI due to the assay inter-
ference with cortisol precursors.
To the best of our knowledge, there are no studies evaluat-
ing cortisol response after LDCT by R2 and LC-MS/MS in
healthy subjects. It may be difficult to diagnose AI, especially
when SAI is suspected, since the additional guidance based on
high basal ACTH concentrations is lacking, and no tests (in-
cluding ITT) correctly classify all patients [23].
The current guidelines highlight that for a correct AI
diagnosis, it is essential to understand the pre-test probabil-
ity of disease and the test limitations and to apply proper
clinical assessment and follow-up. Nevertheless, clinicians
also need reliable biochemical data. The introduction into
the clinical practice of more modern methods for cortisol
measurement, such as R2 that has been calibrated on GC-
MS/MS, makes the interpretation of cortisol stimulatory
tests even more difficult in the absence of new cut-offs.
Indeed, it is well known that LC-MS/MS and GC-MS/
MS, the gold standard procedures for steroid measurement
due to their lower cross-reactivity with other steroids, pro-
vide lower cortisol concentrations than older assays [14, 15,
18]. As a consequence, the cortisol cut-off to diagnose AI
needs to be redefined.
The main limitations of our study are the lack of a control
group for both SDCT and LDCT, the low number of included
patients, and the use of two different tests for the diagnosis of
AI (SDCT and LDCT), which could have introduced a bias.
Notwithstanding these limitations, the present data may be
useful in clinical practice, since they confirm that a much
lower cortisol cut-off after ACTH stimulation needs to be
adopted when cortisol is measured by R2.
In conclusion, cortisol concentrations measured by the R2
method are similar to those measured by LC-MS/MS, and
their use results in lower cortisol concentrations compared
with R1. This could lead to AI misdiagnosis if the current
cut-off of 500 nmol/L (18 μg/dL) is used. New clinically
derived thresholds are not yet available, and this has to be
taken into account when interpreting stimulated cortisol peak
concentrations in clinical practice.
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